Challenges and Opportunities in Valvular Heart Disease: From Molecular Mechanisms to the Community.
作者信息
Aikawa Elena, Blaser Mark C, Singh Sasha A, Levine Robert A, Yacoub Magdi H
机构信息
Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (E.A., M.C.B., S.A.S.), Harvard Medical School, Boston.
Center for Excellence in Vascular Biology, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (E.A.), Harvard Medical School, Boston.
出版信息
Arterioscler Thromb Vasc Biol. 2024 Apr;44(4):763-767. doi: 10.1161/ATVBAHA.123.319563. Epub 2024 Mar 27.
Abstract
摘要
相似文献
1
Challenges and Opportunities in Valvular Heart Disease: From Molecular Mechanisms to the Community.心脏瓣膜病的挑战与机遇：从分子机制到社区
Arterioscler Thromb Vasc Biol. 2024 Apr;44(4):763-767. doi: 10.1161/ATVBAHA.123.319563. Epub 2024 Mar 27.
2
Epidemiology of Valvular Heart Disease.瓣膜性心脏病的流行病学。
Surg Clin North Am. 2022 Jun;102(3):517-528. doi: 10.1016/j.suc.2022.01.008.
3
Current medical management of valvular heart disease.心脏瓣膜病的当前医学管理
Cleve Clin J Med. 2001 Oct;68(10):881-7. doi: 10.3949/ccjm.68.10.881.
4
Percutaneous therapies for valvular heart disease.心脏瓣膜病的经皮治疗
Cardiovasc Pathol. 2006 May-Jun;15(3):123-9. doi: 10.1016/j.carpath.2006.02.004.
5
Morphologic features of the normal and abnormal mitral valve.正常和异常二尖瓣的形态学特征。
Am J Cardiol. 1983 Mar 15;51(6):1005-28. doi: 10.1016/s0002-9149(83)80181-7.
6
Valvular Heart Disease: New Concepts in Pathophysiology and Therapeutic Approaches.心脏瓣膜病：病理生理学与治疗方法的新概念
Annu Rev Med. 2023 Jan 27;74:155-170. doi: 10.1146/annurev-med-042921-122533. Epub 2022 Nov 18.
7
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2014年美国心脏协会/美国心脏病学会瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 10;129(23):e521-643. doi: 10.1161/CIR.0000000000000031. Epub 2014 Mar 3.
8
Recognition and management of emergencies in valvular heart disease.心脏瓣膜病急症的识别与处理
Med Clin North Am. 1979 Jan;63(1):155-72. doi: 10.1016/s0025-7125(16)31722-9.
9
[Valve prosthesis in cardiac defects: indications and potentials].[心脏缺损中的瓣膜假体：适应症和潜力]
Vutr Boles. 1980;19(2):14-21.
10
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2014年美国心脏协会/美国心脏病学会瓣膜性心脏病患者管理指南：执行摘要：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 10;129(23):2440-92. doi: 10.1161/CIR.0000000000000029. Epub 2014 Mar 3.
引用本文的文献
1
Recent Advances in Deciphering Normal and Diseased Aortic Valve Biology Using Transcriptomic Technologies.利用转录组技术解析正常和病变主动脉瓣生物学的最新进展
J Cell Mol Med. 2025 Sep;29(17):e70835. doi: 10.1111/jcmm.70835.
2
Calcific aortic stenosis: omics-based target discovery and therapy development.钙化性主动脉瓣狭窄：基于组学的靶点发现与治疗开发。
Eur Heart J. 2025 Feb 14;46(7):620-634. doi: 10.1093/eurheartj/ehae829.
本文引用的文献
1
Intracellular proteomics and extracellular vesiculomics as a metric of disease recapitulation in 3D-bioprinted aortic valve arrays.三维生物打印主动脉瓣阵列中疾病再现的细胞内蛋白质组学和细胞外囊泡组学标志物。
Sci Adv. 2024 Mar;10(9):eadj9793. doi: 10.1126/sciadv.adj9793. Epub 2024 Feb 28.
2
Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.主要促成因子超家族结构域包含物 5 的抑制作用可减少心脏瓣膜病中脂蛋白(a)的摄取和钙化。
Circulation. 2024 Jan 30;149(5):391-401. doi: 10.1161/CIRCULATIONAHA.123.066822. Epub 2023 Nov 8.
3
Multiscale structure and function of the aortic valve apparatus.主动脉瓣装置的多尺度结构与功能
Physiol Rev. 2024 Oct 1;104(4):1487-1532. doi: 10.1152/physrev.00038.2022. Epub 2023 Sep 21.
4
Bicuspid aortic valve: long-term morbidity and mortality.二叶式主动脉瓣：长期发病率和死亡率。
Eur Heart J. 2023 Nov 14;44(43):4549-4562. doi: 10.1093/eurheartj/ehad477.
5
Multiomics of Tissue Extracellular Vesicles Identifies Unique Modulators of Atherosclerosis and Calcific Aortic Valve Stenosis.组织细胞外囊泡的多组学分析鉴定动脉粥样硬化和钙化性主动脉瓣狭窄的独特调节因子。
Circulation. 2023 Aug 22;148(8):661-678. doi: 10.1161/CIRCULATIONAHA.122.063402. Epub 2023 Jul 10.
6
Abnormal Mechanics Relate to Myocardial Fibrosis and Ventricular Arrhythmias in Patients With Mitral Valve Prolapse.异常力学与二尖瓣脱垂患者心肌纤维化和室性心律失常相关。
Circ Cardiovasc Imaging. 2023 Apr;16(4):e014963. doi: 10.1161/CIRCIMAGING.122.014963. Epub 2023 Apr 18.
7
Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program.多祖裔全基因组关联研究主动脉瓣狭窄在百万退伍军人计划中鉴定出多个新的位点。
Circulation. 2023 Mar 21;147(12):942-955. doi: 10.1161/CIRCULATIONAHA.122.061451. Epub 2023 Feb 20.
8
Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity.Sortilin 通过诱导间质细胞异质性增强主动脉瓣疾病的纤维化和钙化。
Eur Heart J. 2023 Mar 7;44(10):885-898. doi: 10.1093/eurheartj/ehac818.
9
Bioprosthetic heart valve structural degeneration associated with metabolic syndrome: Mitigation with polyoxazoline modification.生物心脏瓣膜结构退化与代谢综合征相关：聚恶唑啉修饰的缓解作用。
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2219054120. doi: 10.1073/pnas.2219054120. Epub 2022 Dec 27.
10
Research Opportunities in the Treatment of Mitral Valve Prolapse: JACC Expert Panel.二尖瓣脱垂治疗的研究机会：美国心脏病学会专家小组。
J Am Coll Cardiol. 2022 Dec 13;80(24):2331-2347. doi: 10.1016/j.jacc.2022.09.044.
Zotero 插件